{"prompt": "['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.doc:', 'Interventional Trials statement (SPIRIT, www.spirit-statement.org/). The trial results will be published in', \"an open-access journal, in accordance with the NIHR's policy on open-access research. The study will be\", 'reported following the Consolidated Standards of Reporting Trials guideline (CONSORT, www.consort-', 'statement.org), in particular the extensions for non-pharmacological interventions, patient-reported', 'outcomes and pilot and feasibility studies. The Template for Intervention Description and Replication', '(TIDieR) statement will be used for reporting the intervention, 57 ensuring that replication is possible.', '20. DEVELOPMENT OF A NEW PRODUCT/PROCESS OR THE GENERATION OF INTELLECTUAL', 'PROPERTY', 'Ownership of IP generated by employees of the University vests in the University. The protection and', \"exploitation of any new IP is managed by the University's technology transfer office, Oxford University\", 'Innovations.', '21. ARCHIVING', 'During the clinical trial and after trial closure the Investigator will maintain adequate and accurate', 'records to enable the conduct of the clinical trial and the quality of the research data to be evaluated', 'and verified. All essential documents will be stored in such a way that ensures that they are readily', 'available, upon request for the minimum period required by national legislation or for longer if needed.', 'The medical files of trial subjects will be retained in accordance with applicable national legislation and', 'the host institution policy.', 'Retention and storage of laboratory records for clinical trial samples will also follow these guidelines.', \"It is the University of Oxford's policy to store data for a minimum of 3 years from publication.\", 'Investigators may not archive or destroy study essential documents or samples without written', 'instruction from the trial office.', 'Clinical Research Protocol Template version 14.0', 'Page 49 of 65', 'C', 'Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.docr', '22. REFERENCES', '1) Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in', 'the UK until 2035. Br J Cancer. 2016;115(9):1147-55', '2) Hirst A, Philippou Y, Blazeby J, Campbell B Campbell M, Feinberg J, et al. No Surgical Innovation', 'Without Evaluation: Evolution and Further Development of the IDEAL Framework and', 'Recommendations. Ann Surg. 2019;269(2):211-220.', '3) Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP, et al. Glioblastoma in', 'England: 2007-2011. Eur J Cancer. 2015;51:533-42.', '4) Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus', 'concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.', '5)', 'NICE Guideline [NG99] : Brain tumours (primary) and brain metastases in adults. July, 2018.', '6)', 'Cancer Research UK \"Beating Cancer Sooner\" - Our Research Strategy. 2014, CRUK.', '7) Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an', 'important measure of population burden and should be considered when allocating research', 'funds. Br J Cancer. 2005;92(2):241-45.', \"8) Creighton H, Beach B, Bamford SM. Rethinking Cancer The big '''quantifying the social and\", 'economic impact. September, 2015.', '9) Cihoric N, Tsikkinis A, Minniti G, Lagerwaard FJ, Herrlinger U, Mathier E, et al. Current status and', 'perspective of interventional clinical trials for glioblastoma - analysis of clinical trials.gov.', 'Radiation Oncology. 2017;12(1):1.', '10) House of Commons Petitions Committee Funding for research into brain tumours: Government', \"Responses to the Petitions Committee's First Report of Session 2015-2016. First Special Report of\", 'Session 2016-2017.', '11) Report of the Task and Finish Working Group on Brain Tumour Research. Department of Health', 'and Social Care, 2018.', '12) Tessa Jowell Brain-MATRIX: British feasibility study of molecular stratification and targeted', 'therapy to optimise the clinical management of patients with glioma by enhancing clinical', 'outcomes, reducing avoidable toxicity, improving management of post-operative residual and', 'recurrent disease and improving survivorship. The Brain Tumour Charity.', '13) James Lind Alliance Neuro-oncology Top 10 Priorities.', '14) Dirven L, Koekkoek JAF, Reijneveld JC, Taphoorn MJB. Health-related quality of life in brain', 'tumour patients:as an endpoint in clinical trials and its value in clinical care. Expert Review of', 'Quality of Life in Cancer Care. 2016;1(1):37-44.', 'Clinical Research Protocol Template version 14.0', 'Page 50 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}